Vai al contenuto
At 5 years, CARB-X celebrates progress on antibiotic development 2020 Antibacterial agents in clinical and preclinical development: an overview and analysis Reimbursement models to tackle market failures for antimicrobials: Approaches taken in France, Germany, Sweden, the United Kingdom, and the United States Precarious antibiotics supply situation: Will the Covid19 Pandemic change anything? (translation D–>E)Financing Pull Mechanisms for Antibiotic-Related Innovation: Opportunities for Europe 71 : 1994 (2020)No money for new drugs Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonu s73 : 421-428 (2020)Needs assessment for novel Gram-negative antibiotics in US hospitals: a retrospective cohort study Antibiotic development — economic, regulatory and societal challenges 18 : 267 (2020)The global preclinical antibacterialpipeline Priority pathogens and the antibiotic pipeline: an update 90 : 151 (2020)Biological Risks in Switzerland: Antibiotic resistances The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later Lancet Infectious Diseases , 11 February 2020Crisis Looms in Antibiotics as Drug Makers Go Bankrupt New York Times (26.12.2019)CAESAR annual report 2018 Swiss Antibiotic Resistance Report 2018 Incentivising a sustainable response to the threat of AMR Chimeric peptidomimetic antibiotics against Gram-negative bacteria
